Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions

被引:2
作者
Hsiung, Kuei-Ching [1 ]
Chiang, Huan-Jung [1 ,2 ]
Reinig, Sebastian [1 ]
Shih, Shin-Ru [1 ,3 ,4 ,5 ]
机构
[1] Chang Gung Univ, Coll Med, Res Ctr Emerging Viral Infect, Taoyuan 33302, Taiwan
[2] Chang Gung Univ, Grad Inst Biomed Sci, Coll Med, Taoyuan 33302, Taiwan
[3] Linkou Chang Gung Mem Hosp, Dept Lab Med, Taoyuan 33305, Taiwan
[4] Chang Gung Univ, Coll Med, Dept Med Biotechnol & Lab Sci, Taoyuan 33302, Taiwan
[5] Chang Gung Univ Sci & Technol, Grad Inst Hlth Ind Technol, Res Ctr Chinese Herbal Med, Res Ctr Food & Cosmet Safety,Coll Human Ecol, Taoyuan 33303, Taiwan
关键词
RNA virus; vaccine platform; RNA virus vaccines; SARS-CoV-2; influenza virus; enterovirus; dengue virus; Zika virus; immune response; T-CELL RESPONSES; ACUTE RESPIRATORY SYNDROME; COMPLETE GENOME SEQUENCE; INFLUENZA-VIRUS; IMMUNE-RESPONSES; SARS-COV-2; VACCINE; SUBUNIT VACCINES; ANTIGENIC DRIFT; VECTOR; LIVE;
D O I
10.3390/vaccines12121345
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The development of vaccines against RNA viruses has undergone a rapid evolution in recent years, particularly driven by the COVID-19 pandemic. This review examines the key roles that RNA viruses, with their high mutation rates and zoonotic potential, play in fostering vaccine innovation. We also discuss both traditional and modern vaccine platforms and the impact of new technologies, such as artificial intelligence, on optimizing immunization strategies. This review evaluates various vaccine platforms, ranging from traditional approaches (inactivated and live-attenuated vaccines) to modern technologies (subunit vaccines, viral and bacterial vectors, nucleic acid vaccines such as mRNA and DNA, and phage-like particle vaccines). To illustrate these platforms' practical applications, we present case studies of vaccines developed for RNA viruses such as SARS-CoV-2, influenza, Zika, and dengue. Additionally, we assess the role of artificial intelligence in predicting viral mutations and enhancing vaccine design. The case studies underscore the successful application of RNA-based vaccines, particularly in the fight against COVID-19, which has saved millions of lives. Current clinical trials for influenza, Zika, and dengue vaccines continue to show promise, highlighting the growing efficacy and adaptability of these platforms. Furthermore, artificial intelligence is driving improvements in vaccine candidate optimization and providing predictive models for viral evolution, enhancing our ability to respond to future outbreaks. Advances in vaccine technology, such as the success of mRNA vaccines against SARS-CoV-2, highlight the potential of nucleic acid platforms in combating RNA viruses. Ongoing trials for influenza, Zika, and dengue demonstrate platform adaptability, while artificial intelligence enhances vaccine design by predicting viral mutations. Integrating these innovations with the One Health approach, which unites human, animal, and environmental health, is essential for strengthening global preparedness against future RNA virus threats.
引用
收藏
页数:32
相关论文
共 50 条
  • [1] HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions
    Rubens, Muni
    Ramamoorthy, Venkataraghavan
    Saxena, Anshul
    Shehadeh, Nancy
    Appunni, Sandeep
    JOURNAL OF IMMUNOLOGY RESEARCH, 2015, 2015
  • [2] Targets and strategies for vaccine development against dengue viruses
    Wang, Wen-Hung
    Urbina, Aspiro Nayim
    Lin, Chih-Yen
    Yang, Zih-Syuan
    Assavalapsakul, Wanchai
    Thitithanyanont, Arunee
    Lu, Po-Liang
    Chen, Yen-Hsu
    Wang, Sheng-Fan
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 144
  • [3] Vaccine strategies for glioblastoma: progress and future directions
    Jackson, Christopher
    Ruzevick, Jacob
    Brem, Henry
    Lim, Michael
    IMMUNOTHERAPY, 2013, 5 (02) : 155 - 167
  • [4] Vaccine Advances against Venezuelan, Eastern, and Western Equine Encephalitis Viruses
    Stromberg, Zachary R.
    Fischer, Will
    Bradfute, Steven B.
    Kubicek-Sutherland, Jessica Z.
    Hraber, Peter
    VACCINES, 2020, 8 (02)
  • [5] Tuberculosis prevention: current strategies and future directions
    Vasiliu, Anca
    Martinez, Leonardo
    Gupta, Rishi K.
    Hamada, Yohhei
    Ness, Tara
    Kay, Alexander
    Bonnet, Maryline
    Sester, Martina
    Kaufmann, Stefan H. E.
    Lange, Christoph
    Mandalakas, Anna M.
    CLINICAL MICROBIOLOGY AND INFECTION, 2024, 30 (09) : 1123 - 1130
  • [6] Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses
    Liu, Yalan
    Li, Yuncheng
    Hu, Qinxue
    VACCINES, 2023, 11 (07)
  • [7] Vaccine Technologies Against Avian Influenza: Current Approaches and New Directions
    Ross, Kathleen A.
    Huntimer, Lucas M.
    Ramirez, Julia E. Vela
    Adams, Justin R.
    Carpenter, Susan L.
    Kohut, Marian L.
    Bronich, Tatiana
    Webby, Richard
    Legge, Kevin L.
    Mallapragada, Surya K.
    Wannemuehler, Michael J.
    Narasimhan, Balaji
    JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 2014, 10 (09) : 2261 - 2294
  • [8] Development of a Vaccine Against Pandemic Influenza Viruses: Current Status and Perspectives
    Ilyinskii, Petr O.
    Thoidis, Galini
    Shneider, Alexander M.
    INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2008, 27 (06) : 392 - 426
  • [9] Current Dengue Virus Vaccine Developments and Future Directions
    Anumanthan, Govindaraj
    Sahay, Bikash
    Mergia, Ayalew
    VIRUSES-BASEL, 2025, 17 (02):
  • [10] Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development
    Chu, Ki-Back
    Quan, Fu-Shi
    VACCINES, 2021, 9 (05)